Totals
- Total revenue
- $743
- Total expenses
- not reported
- Contributions and grants received
- not reported
- Grants paid
- not reported
- Program service revenue
- not reported
- Membership dues (line 3)
- not reported
- Investment income (line 4)
- not reported
- Gain or loss on sale of assets (line 5c)
- not reported
- Gaming and fundraising events, net (line 6d)
- not reported
- Gross profit on inventory sales (line 7c)
- not reported
- Other revenue (line 8)
- $743
- Total assets, end of year
- $18,678
- Total liabilities, end of year
- $0
- Net assets or fund balances, end of year
- $18,678
- Program service expenses (Part III)
- not reported
Mission and programs · 2022
Primary exempt purpose
TO SUPPORT THE MISSION OF TRILOGY,INC.
-
PROVIDE SUPPORT TO TRILOGY, INC.
As filed on the 2022 return.
Listed in Part IV
-
AIMEE FEUSER
PRESIDENT
- Total calculated
- $0
- Hours/week
- 1
-
BRETT COCHRANE
SECRETARY
- Total calculated
- $0
- Hours/week
- 1
-
RICHARD ADELMAN
TREASURER
- Total calculated
- $0
- Hours/week
- 1
-
SUSAN DOIG
VICE PRESIDENT
- Total calculated
- $0
- Hours/week
- 1
-
JEFF FENWICK
DEVELOPMENT CHAIR
- Total calculated
- $0
- Hours/week
- 1
-
SAMANTHA HANDLEY NON-VOTING
TRUSTEE
- Total calculated
- $0
- Hours/week
- 1
-
ANGELA HAINSWORTH NON-VOTING
TRUSTEE
- Total calculated
- $0
- Hours/week
- 1
Compensation is as filed in Part IV of the Form 990-EZ: compensation, contributions to benefit plans, expense account, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990_ez
- Tax year
- 2022
- Filed
- 14 May 2024
- IRS schema version
- 2022v5.0
- Source object
- 202401369349205480
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.